Ignite Creation Date:
2025-12-24 @ 3:28 PM
Ignite Modification Date:
2026-01-03 @ 11:08 PM
Study NCT ID:
NCT02850692
Status:
UNKNOWN
Last Update Posted:
2020-05-26
First Post:
2016-06-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Portal Hypertension and Systemic Endothelial Function
Sponsor:
Hopital Foch
Organization:
Study Overview
Official Title:
Portal Hypertension and Systemic Endothelial Function: Investigation of Systemic Endothelial Dysfunction in Case of Portal Hypertension Associated With Cystic Fibrosis.
Status:
UNKNOWN
Status Verified Date:
2020-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ENDOTH-MUCO
Brief Summary:
Cystic fibrosis can affect organs other than the lungs. Liver disease affects about 30% of patients: its main manifestation is the development of portal hypertension (PHT). The pathophysiology of this comorbidity is still poorly understood. It was previously considered secondary to the formation of biliary cirrhosis but another hypothesis would be that of a primitive pathology of venous vessels may cause the gradual emergence of portal hypertension without cirrhosis. Evidence indiscutly suggest that cystic fibrosis is associated with a specific endothelial dysfunction, especially as the CFTR (Cystic Fibrosis Transmembrane conductance Regulator) protein is expressed on the surface of endothelial cells. The investigators hypothesize that liver disease related to PHT-associated cystic fibrosis is associated with systemic endothelial dysfunction.
The aim is:
To demonstrate a systemic endothelial dysfunction in patients with cystic fibrosis when associated with PHT.
To study the correlations between measures of systemic endothelial function and serum markers of endothelial dysfunction and between measures of liver stiffness and systemic endothelial function.
The aim is:
To demonstrate a systemic endothelial dysfunction in patients with cystic fibrosis when associated with PHT.
To study the correlations between measures of systemic endothelial function and serum markers of endothelial dysfunction and between measures of liver stiffness and systemic endothelial function.
Detailed Description:
Prospective , monocentric study, with four groups of patients:
* Patients with cystic fibrosis and PHT
* Cystic fibrosis patients without PHT
* Patients free from cystic fibrosis with PHT from other causes
* Healthy controls. One study visit, no follow-up.
During the visit the following examinations will be performed:
* Collection of a blood sample of 21 mL.
* Liver eElastography achieved through hardware FibroScan® -
* Measurement of endothelial function with Endopat®
* Contrast-enhanced tomography. Abdominal CT scan will not be performed in healthy volunteers.
* Patients with cystic fibrosis and PHT
* Cystic fibrosis patients without PHT
* Patients free from cystic fibrosis with PHT from other causes
* Healthy controls. One study visit, no follow-up.
During the visit the following examinations will be performed:
* Collection of a blood sample of 21 mL.
* Liver eElastography achieved through hardware FibroScan® -
* Measurement of endothelial function with Endopat®
* Contrast-enhanced tomography. Abdominal CT scan will not be performed in healthy volunteers.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2015-A01872-47 | OTHER | ANSM | View |